Independent · Validated · 30 years
Empowering smarter decisions in biopharma.
Strategic market insights for global biopharma and life science — delivered by analysts, consultants, and a network of 750+ industry decision-makers.
We deliver independent, validated market insights that enable executives in biopharma and bioprocessing to make informed, revenue-driven decisions across manufacturing, supply chains, innovation, and commercialization.
By the numbers
What we do
Core services for market growth.
Three integrated practices that move from primary signal to strategic action — built for biopharma operators, investors, and bioprocessing leaders.
Primary-source intelligence that decisions can stand on.
Direct interviews with global decision-makers, structured against benchmarks built over three decades of biomanufacturing study.
Talk to a research lead →- Market sizing & forecastingBottom-up models grounded in plant-level capacity and buyer demand.
- New product developmentConcept testing and adoption modeling with target buyers.
- Pricing & value quantificationWillingness-to-pay calibrated against switching cost.
- Voice of CustomerStructured qualitative work with the people who buy and specify.
- Competitive landscapeRanked, sourced, defensible positions across the field.
Advisory work for high-stakes moves.
Used to support M&A committees, market-entry steering groups, and platform-investment decisions.
Brief our advisory team →- M&A due diligenceMarket & technology validation with primary signal.
- Market entry strategyCountry, segment, and channel design — including China.
- Tech adoption modelingS-curve and switching-cost economics.
- CDMO bioprocessing expertiseCapacity, modality, and partnership strategy.
- Competitive threat assessmentDisruption pathways and defensive response plans.
Databases and benchmarks the industry already cites.
Curated, validated, and refreshed — designed to plug into your strategy work and corporate decks.
Browse the resource library →- Global biomanufacturing dataCapacity, modality, geography — refreshed annually.
- CDMO competitive analysisTop 450 CDMOs with strategic profiles.
- Single-use device suppliersSupplier landscape and adoption signals.
- Annual benchmarking reportsThe reports operators benchmark themselves against.
- Supply chain analysisRisk, redundancy, and modality-specific exposure.
Why BioPlan
Built to reduce the risk of major market decisions.
Translate complex market dynamics into actionable strategy. Move faster, invest smarter — backed by independent, validated primary research.
Independent & unbiased
Three decades of expert analysis, free of conflicts. Our recommendation isn't shaped by a vendor relationship.
Deep industry authority
One of the most cited sources in bioprocessing — used by operators, investors, regulators, and the press.
Validated primary research
A 750-member Industry Council and 77 independent experts give every finding real-world ground truth.
ROI-focused strategy
Every engagement is designed to inform measurable, revenue-generating outcomes — not produce shelfware.
Resources
A working library, not a marketing bookshelf.
Flagship reports, structured databases, and a global expert network — the tools our advisory teams use, available to operators and investors.
01 Network of global industry expertise
A standing panel of decision-makers and an independent consultant bench that lets us field a study in days, not months.
- 750-member Biotechnology Industry Council — global decision-maker panel
- 77 independent consultants & experts
02 Flagship reports
Annual and topical reports the industry benchmarks itself against.
- Annual Biomanufacturing Capacity & Production Report
- Global CDMO Market Analysis
- Biopharmaceutical Technology Platforms
- Gene Therapy & Cell Therapy Manufacturing Insights
- China, India vs US/EU comparative market studies
03 Market databases
Structured, validated, refreshed — designed to plug into corporate strategy work.
- Global BioFacilities database
- Top CDMO facilities database
- Cell & gene therapy manufacturing facilities
- Single-use suppliers intelligence
- China biomanufacturing landscape
- Top1000bio.com database profiling global biopharma facilities
04 Podcasts
BioPlan Podcasts and expert conversations.
Read more →05 Presentations
BioPlan presentations and conference updates.
Read more →06 Publications
Future parent page for BioPlan publication formats. The sub-links below are already marked with target URLs for designer handoff.
Who we serve
Trusted by biopharma leaders for 30 years.
From emerging innovators to multinational biopharma leaders — and the investors who back them.
- Bioprocess equipment manufacturers
- Single-use technology suppliers
- CDMOs
- Emerging biotech innovators
- Private equity & strategic investors
- Multinational pharmaceutical companies
Leadership timeline
Three decades, one focus.
For over 30 years BioPlan has tracked the industry's strategic inflection points, keeping focused on the insights our Clients need.
- 1989
Founded
Rockville-based advisory focus begins.
- 2000
Commercial launches
US and European biopharma markets.
- 2003
Annual reports
Global biomanufacturing benchmark series.
- 2006
China expansion
Local-market intelligence as capacity grows.
- 2012
Facility databases
Global BioFacilities data infrastructure.
- 2015
New modalities
Biosimilars, CDMO, cell and gene therapy.
- 2020
Top 450 CDMOs
Strategic advisory authority and rankings.
- 2025
Advanced medicines
Cell and gene therapy facility databases.
Typical engagements
Recent strategic work.
CDMO · Benchmarking
Global CDMO market ranking & SWOT analysis
Publication-level benchmarking and strategic competitive assessment.
Cell & gene · Forecasting
Gene therapy manufacturing demand forecast
10-year outsourcing and capacity modeling across global markets.
Market entry · China
China competitive landscape study
Market sizing, procurement impact analysis, and regulatory positioning.
Validation · Bioprocess
Alternative Protein-A technology market validation
Adoption modeling, pricing strategy, and demand forecasting.
Strategy · Modular
Modular bioproduction strategy
Market entry and partnership strategy for emerging platforms.
Equipment · Forecasting
Global bioreactor market analysis
Single-use vs multi-use competitive intelligence and growth modeling.
Wireframe notes
About this prototype.
This page is a clickable redesign concept — not BioPlan's live site. A full redesign brief sits alongside this prototype.
Page strategy
- Premium hero with decision-support panel
- Discrete proof metrics, not oversized counters
- Services as tabs to keep the page short
- Decision-risk framing as the central trust story
- Resources as expandable accordion
- Leadership timeline as secondary credibility
Design system
- Warm off-white surface · deep teal-navy ink
- Muted green accent only for confirmations
- Fraunces display · Satoshi body · Inter UI
- Subtle scientific grid in hero only
- Restrained motion — hover lifts, gentle reveals
Interactions
- Sticky nav with services mega-menu
- Mobile menu & smooth-scroll anchors
- Service tabs · resource accordion
- Counters animate once on scroll-in
- Section reveal with prefers-reduced-motion respected
Full brief: BioPlan-homepage-redesign-brief.md in this project directory.
Get in touch
Let's discuss your next strategic initiative.
Tell us about the decision in front of you. We'll suggest a research approach, scope, and a defensible timeline.
BioPlan Associates, Inc.
1 Research Court, Suite 450
Rockville, MD 20850 USA